George T.
Capone
,
MD

George T. Capone, M.D.'s picture
Director, Down Syndrome Clinic
Kennedy Krieger Institute

707 N. Broadway
Baltimore, MD 21205
United States

Centers & Programs

About

Dr. George Capone is a research scientist and director of the Down Syndrome Clinic and Research Center (DSCRC) at Kennedy Krieger Institute and is also an associate professor of pediatrics at the Johns Hopkins University School of Medicine.

Education 

Dr. Capone attended college at Wesleyan University and worked as a research assistant at the Dana Farber Cancer Institute in Boston before obtaining his medical degree from the University of Connecticut in 1983. After a residency and fellowship in pediatrics at the Children's Hospital Medical Center in Cincinnati, Dr. Capone came to Baltimore in 1988 to pursue a fellowship in neurobiology research at Johns Hopkins. Dr. Capone currently serves as the director of Kennedy Krieger Institute's Down Syndrome Clinic and Research Center (DSCRC), and is an attending physician on the institute's comprehensive rehabilitation unit.

Research

Down syndrome is a genetic disorder that occurs in approximately 1 in 733 live births. It is caused most often by an abnormality during cell division in gamete formation called nondysjunction. As a result, the fertilized egg will contain three copies of chromosome 21. The extra chromosome interferes with normal growth and development.

Dr. Capone and his colleagues are committed to research that explores the neurobiologic basis of cognitive impairment and co-morbid neurobehavioral and psychiatric disorders associated with Down syndrome.

Current Research Projects:

  • A multi-center, double-blind placebo study in collaboration with Duke University testing the usefulness of an FDA approved drug, Rivastigmine, on memory and language function in children with Down syndrome ages 10-17 years. Cathleen Weadon, Research Coordinator, (443) 923-9140
  • A multi-center pilot study, in collaboration with Johns Hopkins University for children with Down syndrome ages 7-17 years, to determine the usefulness of computer-based testing to measure visual memory and movement. Some standardized testing will also be performed, and your child's test results will be made available to you. Lisa Toole, Research Coordinator (443) 923-2953.
  • Roche Pharmaceuticals is sponsoring a study at Kennedy Krieger Institute and the Johns Hopkins University for adults with Down syndrome between 18 and 30 years of age. The purpose is to study the safety and tolerability of a new drug that have been developed to improve attention and memory. Carrie Blout, MS, CGC, (410) 502-7535

Research Studies

  • Children and adolescents, ages 10-17, with Down syndrome
  • Individuals, ages 7-17, with Down syndrome (Flyer)
  • Individuals, ages 7-17, with Down syndrome (Brochure)

Related Links

Elsevier Fingerprint Engine Profile for George Capone

Research Publications

Capone GT, Brecher L, Bay M (2016). Guanfacine Use in Children With Down Syndrome and Comorbid Attention-Deficit Hyperactivity Disorder (ADHD) With Disruptive Behaviors. J Child Neurol. 31(8), 957-64. 

Mendioroz M, Do C, Jiang X, Liu C, Darbary HK, Lang CF, Lin J, Thomas A, Abu-Amero S, Stanier P, Temkin A, Yale A, Liu MM, Li Y, Salas M, Kerkel K, Capone G, Silverman W, Yu YE, Moore G, Wegiel J, Tycko B (2015). Trans effects of chromosome aneuploidies on DNA methylation patterns in human Down syndrome and mouse models. Genome Biol. 16, 263. 

Capone GT, Aidikoff JM, Taylor K, Rykiel N (2013). Adolescents and young adults with Down syndrome presenting to a medical clinic with depression: co-morbid obstructive sleep apnea. Am J Med Genet A. 161A(9), 2188-96. 

Capone GT (2010). The emergence of pharmacotherapies for cognitive function in Down syndrome. Am J Med Genet A. 152A(12), 3026-7. 

Trois MS, Capone GT, Lutz JA, Melendres MC, Schwartz AR, Collop NA, Marcus CL (2009). Obstructive sleep apnea in adults with Down syndrome. J Clin Sleep Med. 5(4), 317-23.

Carter JC, Capone GT, Kaufmann WE (2008). Neuroanatomic correlates of autism and stereotypy in children with Down syndrome. Neuroreport. 19(6), 653-6..

Capone GT, Goyal P, Grados MSmith B, Kammann H (2008). Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study. J Dev Behav Pediatr. 29(2), 106-16. 

Ting JC, Roberson ED, Miller ND, Lysholm-Bernacchi A, Stephan DA, Capone GT, Ruczinski I, Thomas GH, Pevsner J (2007). Visualization of uniparental inheritance, Mendelian inconsistencies, deletions, and parent of origin effects in single nucleotide polymorphism trio data with SNPtrio. Hum Mutat. 28(12), 1225-35. 

Carter JC, Capone GT, Gray RM, Cox CS, Kaufmann WE (2007). Autistic-spectrum disorders in Down syndrome: further delineation and distinction from other behavioral abnormalities. Am J Med Genet B Neuropsychiatr Genet. 144B(1), 87-94.

Capone GTGrados MA, Kaufmann WE, Bernad-Ripoll S, Jewell A (2005). Down syndrome and comorbid autism-spectrum disorder: characterization using the aberrant behavior checklist. Am J Med Genet A. 134(4), 373-80.

Kaufmann WE, Cortell R, Kau AS, Bukelis I, Tierney E, Gray RM, Cox C, Capone GT, Stanard P (2004). Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors. Am J Med Genet A. 129A(3), 225-34.